Pune, India -- (SBWIRE) -- 08/10/2018 -- Cancer Immunotherapy Market- Scenario
Cancer Immunotherapy is an advanced paradigm in cancer therapeutics. Cancer immunotherapy works by enhancing the patient's immune system. This is generally accompanied by the administration of synthesized immune proteins. The most common therapeutic areas of cancer immunotherapy are inclusive of breast, prostate, lung cancer, and others. Increasing prevalence of the cancer is one of the major drivers for the market growth during the forecast period. Moreover, growing geriatric population and rising healthcare expenditure, increasing biotech and pharmaceutical sector boosts the market growth. However, lack of awareness and high cost for the services may restrain the market growth.
According to the National Cancer Institute in 2016, an estimated 1,685,210 new cases of cancer were diagnosed in the U.S. and approximately 595,690 people died due to cancer within the region. Moreover, it was estimated that the national healthcare expenditures for cancer care in the U.S. totalled nearly to USD 125 billion in 2010, and it is expected to reach USD 156 billion by 2020. Moreover, growing geriatric population and rising healthcare expenditure will boost the market growth. Additionally, growing biotech and pharmaceutical industries fuels the market growth during the projected period. However, lack of awareness, restriction in therapeutics against different cancers and high cost for the treatment may restrain the market growth from 2017-2023.
The Americas cancer immunotherapy market is expected to grow at an approximate CAGR of 10.1% during the forecast period.
Americas Cancer Immunotherapy Market-Segmentation
The Americas cancer immunotherapy market is segmented on the basis of cancer, therapeutics, and end users.On the basis of the cancer, the market is segmented into lung cancer, prostate cancer, colorectal cancer, head & neck cancer, and others.
Get Sample Copy with latest trends @ https://www.marketresearchfuture.com/sample_request/592
On the basis of the therapeutics, the market is segmented into monoclonal antibodies, immune checkpoint inhibitors, vaccines, non-specific cancer immunotherapies and adjuvants, and others. The monoclonal antibodies segment is sub segmented into naked monoclonal antibodies, conjugated monoclonal antibodies, chemolabeled antibodies, bispecific monoclonal antibodies, and others. The naked monoclonal antibodies segment, by monoclonal antibody segment, is father segmented into alemtuzumab, trastuzumab, and others.
The immune checkpoint inhibitors segment is sub segmented into PD-1 inhibitors, PD-L1 inhibitors, and others. The PD-1 inhibitors segment, by immune checkpoint inhibitors, is sub segmented into pembrolizumab, nivolumab, and others. The PD-L1 inhibitors segment, by immune checkpoint inhibitors, is further segmented into atezolizumab, avelumab, and others. The non-specific cancer immunotherapies and adjuvants segment is sub segmented into cytokines, interleukins, and others.On the basis of the end users, the market is segmented as hospitals & clinics, academic institutes, research organization, and others.
Americas Cancer Immunotherapy Market-Regional Analysis
On regional basis the Americas is divided into North America and Latin America. North America is sub segmented into U.S. and Canada. North America commands for the largest market share for the Americas cancer immunotherapy market due the presence of the U.S. within the region. This large share is also attributed due to the technologically advanced healthcare market in the region which is followed by high prevalence of cancer, increasing development in cancer immunotherapy treatment and rising per capita healthcare expenditure.
Moreover, growing biotechnology, healthcare and life sciences sector within the region fuels the market growth regionally. The total number of the biotechnology industries in the U.S. increased from 2,763 in 2014 and reached 2,772 in 2015. Additionally, the abundance of state of the art laboratories in the U.S. is also facilitating the market growth.
On the other hand, Latin America is the fastest growing region due to the presence of the developing economies within the region, rising healthcare expenditure and huge patient population.
Americas Cancer Immunotherapy Market-Key players
Some of the major player in the market are Amgen Inc. (U.S.), AstraZeneca (U.K), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG (Switzerland), and others.
Get Exclusive Discount @ https://www.marketresearchfuture.com/check-discount/592
Major Points form TOC for Cancer Immunotherapy Market Research Report – Forecast to 2023
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Global Cancer Immunotherapy Market, By Type
Chapter 7. Global Cancer Immunotherapy Market, By Treatment
Chapter 8 Global Cancer Immunotherapy Market, By End User
Chapter 9. Global Cancer Immunotherapy Market, By Region
Chapter 10 Company Landscape
Chapter 11 Company Profiles
Chapter 12 MRFR Conclusion
Chapter 13 Appendix
About Market Research Future
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Phone: +1 646 845 9312